PLGA Ester Capped (50:50)

Price range: $80.00 through $360.00

PLGA Ester Capped (50:50) is a biodegradable poly(lactide-co-glycolide) copolymer with a 50:50 lactide ratio and an ester-terminated end group. Compared with acid-capped PLGA, ester-capped PLGA exhibits lower hydrophilicity and a slower degradation profile at the same molecular weight. PLGA Ester Capped (50:50) is widely used in nanoparticle formulation, controlled drug delivery, microsphere preparation, tissue engineering, and biomaterials research.

Product Name: PLGA Ester Capped (50:50)
Alternative Name: Ester-Terminated PLGA (50:50), End-Capped PLGA (50:50)
Polymer Type: Poly(D,L-lactide-co-glycolide)
Lactide Ratio: 50:50
Molecular Weight: 2k, 5k, 10k, 15k, 20k, 30k, 50k, 100k Da, Custom
End Group: Ester
Appearance: solid
Solubility: Dichloromethane, Chloroform, THF, Acetone, DMF, DMSO
Storage: -20°C, dry and protected from moisture
Purity: Typically ≥99%

 

Description

General Description

PLGA Ester Capped (50:50) is a biodegradable aliphatic polyester composed of equal molar ratios of lactide and glycolide. The polymer terminates with an ester end group rather than a free carboxylic acid, resulting in reduced water uptake, improved hydrolytic stability, and slower degradation compared with the corresponding acid-capped PLGA.

The 50:50 lactide composition provides the fastest degradation among common PLGA copolymers. However, ester end-capping moderates the degradation rate by reducing the autocatalytic effect associated with free carboxyl end groups. This makes PLGA Ester Capped (50:50) suitable for controlled-release formulations requiring improved stability while maintaining relatively rapid biodegradation.

PLGA Ester Capped (50:50) is extensively used for preparing nanoparticles, microspheres, injectable depots, implantable drug delivery systems, tissue engineering scaffolds, and biodegradable medical devices.

Applications

  • Controlled drug delivery
  • Nanoparticle formulation
  • Microsphere preparation
  • Injectable depot systems
  • Controlled-release formulations
  • Tissue engineering
  • Biodegradable implants
  • Vaccine delivery
  • Medical devices
  • Biomaterials research

Features and Benefits

  • Ester-terminated PLGA
  • 50:50 lactide composition
  • Lower hydrophilicity than acid-capped PLGA
  • Improved hydrolytic stability
  • Controlled degradation profile
  • Excellent drug encapsulation capability
  • Excellent biocompatibility
  • Available in multiple molecular weights
  • Suitable for sustained-release formulations

Additional information

Molecular weight

5K, 10K, 20K, 50K, 70K, 100K, 150K, 200k, 300K

Package szie

1g, 5g